Cited by 2,029RNA Research and SplicingAcute Myeloid Leukemia ResearchGenomics and Rare Diseases

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Frequent pathway mutations of splicing machinery in myelodysplasia

Yoshida, Kenichi, Sanada, Masashi, Shiraishi, Yuichi, Nowak, Daniel, Nagata, Yasunobu, Yamamoto, Ryo, Sato, Yusuke, Sato-Otsubo, Aiko, Kon, Ayana, Nagasaki, Masao, Chalkidis, George, Suzuki, Yutaka, Shiosaka, Masashi, Kawahata, Ryoichiro, Yamaguchi, Tomoyuki, Otsu, Makoto, Obara, Naoshi, Sakata-Yanagimoto, Mamiko, Ishiyama, Ken, Mori, Hiraku, Nolte, Florian, Hofmann, Wolf-Karsten, Miyawaki, Shuichi, Sugano, Sumio, Haferlach, Claudia, Koeffler, H. Phillip, Shih, Lee-Yung, Haferlach, Torsten, Chiba, Shigeru, Nakauchi, Hiromitsu, Miyano, Satoru, Ogawa, Seishi·2011·Nature

DOI 10.1038/nature10496

Open this paper in CoChat — free account

Abstract

Myelodysplastic syndromes and related disorders (myelodysplasia) are a heterogeneous group of myeloid neoplasms showing deregulated blood cell production with evidence of myeloid dysplasia and a predisposition to acute myeloid leukaemia, whose pathogenesis is only incompletely understood. Here we report whole-exome sequencing of 29 myelodysplasia specimens, which unexpectedly revealed novel pathway mutations involving multiple components of the RNA splicing machinery, including U2AF35, ZRSR2, SRSF2 and SF3B1. In a large series analysis, these splicing pathway mutations were frequent (∼45 to ∼85%) in, and highly specific to, myeloid neoplasms showing features of myelodysplasia. Conspicuously, most of the mutations, which occurred in a mutually exclusive manner, affected genes involved in the 3'-splice site recognition during pre-mRNA processing, inducing abnormal RNA splicing and compromised haematopoiesis. Our results provide the first evidence indicating that genetic alterations of the major splicing components could be involved in human pathogenesis, also implicating a novel therapeutic possibility for myelodysplasia.

Integrity signals

Registry

Crossref · 10.1038/nature10496

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sequencing technologies – the next generation
Metzker, M. L. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2626 · Cited by 7,066
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
The Spliceosome: Design Principles of a Dynamic RNP Machine
Wahl, M. C., Will, C. L., & Lührmann, R. (2009) · Cell · doi:10.1016/j.cell.2009.02.009 · Cited by 2,665
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C. L., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,457
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 301–400 of 1,002

Integrated molecular profiling of juvenile myelomonocytic leukemia
Murakami, N., Okuno, Y., Yoshida, K., Shiraishi, Y., Nagae, G., Suzuki, K., Narita, A., Sakaguchi, H., Kawashima, N., Wang, X., et al. (2018) · Blood · doi:10.1182/blood-2017-07-798157 · Cited by 108
Self-citation
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 111
The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of actionPreprint
Finci, L. I., Zhang, X., Huang, X., Zhou, Q., Tsai, J., Teng, T., Agrawal, A. A., Chan, B., Irwin, S., Karr, C. D., et al. (2018) · Genes & Development · doi:10.1101/gad.311043.117 · Cited by 108
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders
Visconte, V., Makishima, H., Maciejewski, J. P., & Tiu, R. V. (2012) · Leukemia · doi:10.1038/leu.2012.130 · Cited by 115
Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells
Unni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Ferrarone, J. R., Lockwood, W. W., & VARMUS, H. E. (2018) · eLife · doi:10.7554/elife.33718 · Cited by 111
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Inoue, D., Polaski, J. T., Taylor, J., Castel, P., Chen, S., Kobayashi, S. S., Hogg, S. J., Hayashi, Y., Pineda, J. M. B., Marabti, E. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00828-9 · Cited by 107
Large-scale analysis of branchpoint usage across species and cell linesPreprint
Taggart, A. J., Lin, C., Shrestha, B., Heintzelman, C., Kim, S. W., & Fairbrother, W. G. (2017) · Genome Research · doi:10.1101/gr.202820.115 · Cited by 111
A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets
Adamia, S., Haibe-Kains, B., Pilarski, P. M., Bar-Natan, M., Pevzner, S., Avet-Loiseau, H., Lode, L., Verselis, S., Fox, E. A., Burke, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0956 · Cited by 106
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
Gandhi, A. K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12622 · Cited by 106
Myelodysplastic syndromes: moving towards personalized management
Hellström‐Lindberg, E., Tobiasson, M., & Greenberg, P. L. (2020) · Haematologica · doi:10.3324/haematol.2020.248955 · Cited by 109
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome
Colla, S., Ong, D. S. T., Ogoti, Y., Marchesini, M., Mistry, N. A., Clise-Dwyer, K., Ang, S. A., Storti, P., Viale, A., Giuliani, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.007 · Cited by 105
Mutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 108
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia
Meggendorfer, M., Haferlach, T., Alpermann, T., Jeromin, S., Haferlach, C., Kern, W., & Schnittger, S. (2014) · Haematologica · doi:10.3324/haematol.2014.113159 · Cited by 105
Self-citation
Intergenically Spliced Chimeric RNAs in Cancer
Jia, Y., Xie, Z., & Li, H. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.006 · Cited by 104
Splicing factor mutations in hematologic malignancies
Chen, S., Benbarche, S., & Abdel-Wahab, O. I. (2021) · Blood · doi:10.1182/blood.2019004260 · Cited by 109
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)
Saber, W., Cutler, C. S., Nakamura, R., Zhang, M., Atallah, E. L., Rizzo, J. D., Maziarz, R. T., Cortes, J. E., Kalaycio, M. E., & Horowitz, M. M. (2013) · Blood · doi:10.1182/blood-2013-04-496778 · Cited by 104
Loss of function mutations in RPL27 and RPS27 identified by whole‐exome sequencing in Diamond‐Blackfan anaemia
Wang, R., Yoshida, K., Toki, T., Sawada, T., Uechi, T., Okuno, Y., Sato‐Otsubo, A., Kudo, K., Kamimaki, I., Kanezaki, R., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13229 · Cited by 103
Self-citation
Alternative Splicing as a Target for Cancer Treatment
Martínez-Montiel, N., Rosas-Murrieta, N. H., Anaya-Ruíz, M., Monjaraz-Guzmán, E., & Martínez-Contreras, R. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020545 · Cited by 107
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Bielski, C. M., Donoghue, M. T. A., Gadiya, M. M., Hanrahan, A. J., Won, H. H., Chang, M. T., Jonsson, P., Penson, A. V., Gorelick, A. N., Harris, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.003 · Cited by 108
Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma
Polprasert, C., Takeuchi, Y., Kakiuchi, N., Yoshida, K., Assanasen, T., Sitthi, W., Bunworasate, U., Pirunsarn, A., Wudhikarn, K., Lawasut, P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028340 · Cited by 105
Self-citation
RNA-Binding Proteins Hold Key Roles in Function, Dysfunction, and Disease
Kelaini, S., Chan, C., Cornelius, V. A., & Margariti, A. (2021) · Biology · doi:10.3390/biology10050366 · Cited by 94
Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics
Qiu, P., Zhou, Y., Oyang, L., Wu, N., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., Ma, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.010 · Cited by 109
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 104
How we treat higher-risk myelodysplastic syndromes
Sekeres, M. A., & Cutler, C. S. (2013) · Blood · doi:10.1182/blood-2013-08-496935 · Cited by 102
An evolutionary perspective on chronic myelomonocytic leukemia
Itzykson, R., & Solary, É. (2013) · Leukemia · doi:10.1038/leu.2013.100 · Cited by 108
Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis
Herold, T., Metzeler, K. H., Vosberg, S., Hartmann, L., Röllig, C., Stölzel, F., Schneider, S., Hubmann, M., Zellmeier, E., Ksienzyk, B., et al. (2014) · Blood · doi:10.1182/blood-2013-12-540716 · Cited by 102
Signal Transduction in Ribosome Biogenesis: A Recipe to Avoid Disaster
Piazzi, M., Bavelloni, A., Gallo, A., Faenza, I., & Blalock, W. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112718 · Cited by 109
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
Iwai, K., Yaguchi, M., Nishimura, K., Yamamoto, Y., Tamura, T., Nakata, D., Dairiki, R., Kawakita, Y., Mizojiri, R., Ito, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708289 · Cited by 101
SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing
Komeno, Y., Huang, Y.-J., Qiu, J., Lin, L., Xu, Y., Zhou, Y., Chen, L., Monterroza, D. D., Li, H., DeKelver, R. C., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00202-15 · Cited by 104
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
Mughal, T. I., Cross, N. C. P., Padron, E., Tiu, R. V., Savona, M. R., Malcovati, L., Tibes, R., Komrokji, R. S., Kiladjian, J., Garcia-Manero, G., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.114660 · Cited by 102
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Patnaik, M. M., & Tefferi, A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26455 · Cited by 102
Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review
Patnaik, M. M., Parikh, S. A., Hanson, C. A., & Tefferi, A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12756 · Cited by 99
Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth
Chen, Y., Huang, Q., Liu, W., Zhu, Q., Cui, C., Xu, L., Guo, X. L., Wang, P., Liu, J., Dong, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04815-3 · Cited by 99
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice
Dezern, A. E., Malcovati, L., & Ebert, B. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239083 · Cited by 102
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Patnaik, M. M., & Tefferi, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27271 · Cited by 102
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts
Nikpour, M., Scharenberg, C., Liu, A., Conte, S., Karimi, M., Blanco, T. M., Giai, V., Fernández‐Mercado, M., Papaemmanuil, E., Högstrand, K., et al. (2012) · Leukemia · doi:10.1038/leu.2012.298 · Cited by 101
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
Steensma, D. P. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0140-3 · Cited by 99
The development and application of small molecule modulators of SF3b as therapeutic agents for cancer
Webb, T. R., Joyner, A. S., & Potter, P. M. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.07.013 · Cited by 99
Ribosomal Proteins Rpl22 and Rpl22l1 Control Morphogenesis by Regulating Pre-mRNA Splicing
Zhang, Y., O’Leary, M. N., Peri, S., Wang, M., Zha, J., Melov, S., Kappes, D. J., Feng, Q., Rhodes, J., Amieux, P. S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.034 · Cited by 98
The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulationPreprint
Palangat, M., Anastasakis, D. G., Fei, D. L., Lindblad, K. E., Bradley, R. K., Hourigan, C. S., Hafner, M., & Larson, D. R. (2019) · Genes & Development · doi:10.1101/gad.319590.118 · Cited by 101
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
Yip, B. H., Steeples, V., Repapi, E., Armstrong, R. N., Llorian, M., Roy, S., Shaw, J. M., Dolatshad, H., Taylor, S., Verma, A. K., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91363 · Cited by 99
Self-citation
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Yan, K.-S., Lin, C., Liao, T.-W., Peng, C.-M., Lee, S.-C., Liu, Y., Chan, W. P., & Chou, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061172 · Cited by 101
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML
Yoshimi, A., Balasis, M. E., Vedder, A., Feldman, K., Ma, Y., Zhang, H., Lee, S. C.-W., Letson, C. T., Niyongere, S., Lu, S. X., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763219 · Cited by 101
Alternative Splicing Dynamics in Plant Adaptive Responses to Stress
Alhabsi, A., Ling, Y., Crespi, M. D., Reddy, A. S. N., & Mahfouz, M. M. (2025) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-083123-090055 · Cited by 99
Spliceosomopathies: Diseases and mechanisms
Griffin, C., & Saint‐Jeannet, J. (2020) · Developmental Dynamics · doi:10.1002/dvdy.214 · Cited by 96
DNA Repair and Therapeutic Strategies in Cancer Stem Cells
Gillespie, M. S., Ward, C. M., & Davies, C. C. (2023) · Cancers · doi:10.3390/cancers15061897 · Cited by 101
Abnormal erythropoiesis and the pathophysiology of chronic anemia
Koury, M. J. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.01.002 · Cited by 98
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
Molenaar, R. J., Thota, S., Nagata, Y., Patel, B. J., Clemente, M. J., Przychodzen, B. P., Hirsch, C. M., Viny, A. D., Hosano, N., Bleeker, F. E., et al. (2015) · Leukemia · doi:10.1038/leu.2015.91 · Cited by 101
Self-citation
Emerging concepts of epigenetic dysregulation in hematological malignancies
Ntziachristos, P., Abdel-Wahab, O. I., & Aifantis, I. (2016) · Nature Immunology · doi:10.1038/ni.3517 · Cited by 99
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
Liang, Y., Tebaldi, T., Rejeski, K., Joshi, P. M., Stefani, G., Taylor, A., Song, Y., Vasic, R., Maziarz, J. D., Balasubramanian, K., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0152-7 · Cited by 98
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
Chen, T.-C., Hou, H.-A., Chou, W.-C., Tang, J.-L., Kuo, Y.-Y., Chen, C.-Y., Tseng, M.-H., Huang, C.-F., Lai, Y.-J., Chiang, Y.-C., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2013.74 · Cited by 99
Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
Broséus, J., Alpermann, T., Wulfert, M., Florensa, L., Jeromin, S., Lippert, É., Rozman, M., Lifermann, F., Großmann, V., Haferlach, T., et al. (2013) · Leukemia · doi:10.1038/leu.2013.120 · Cited by 96
Self-citation
The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Larsson, C. A., Cote, G. J., & Quintás‐Cardama, A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0695 · Cited by 97
Genomics of chronic neutrophilic leukemia
Maxson, J. E., & Tyner, J. W. (2016) · Blood · doi:10.1182/blood-2016-10-695981 · Cited by 95
Most human introns are recognized via multiple and tissue-specific branchpointsPreprint
Pineda, J. M. B., & Bradley, R. K. (2018) · Genes & Development · doi:10.1101/gad.312058.118 · Cited by 100
Alternative RNA splicing and cancer
Liu, S., & Cheng, C. (2013) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1178 · Cited by 96
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
Hou, H., Tsai, C., Lin, C., Chou, W., Kuo, Y., Liu, C., Tseng, M., Peng, Y., Liu, M.-C., Liu, C., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0074-7 · Cited by 95
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
Bono, E. B., McLornan, D. P., Travaglino, E., Gandhi, S., Gallì, A., Khan, A. A., Kulasekararaj, A. G., Boveri, E., Raj, K. K., Elena, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0457-1 · Cited by 93
Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
Yu, J., Li, Y., Li, T., Li, Y., Xing, H., Sun, H., Sun, L., Wan, D., Liu, Y., Xie, X., et al. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0158-5 · Cited by 95
Splicing Patterns in SF3B1 -Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes
Bigot, J., Lalanne, A. I., Lucibello, F., Gueguen, P., Houy, A., Dayot, S., Ganier, O., Gilet, J., Tosello, J., Némati, F., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0555 · Cited by 94
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS
Inoue, D., Kitaura, J., Matsui, H., Hou, H.-A., Chou, W.-C., Nagamachi, A., Kawabata, K. C., Togami, K., Nagase, R., Horikawa, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.301 · Cited by 92
An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growthPreprint
Adler, A. S., McCleland, M. L., Yee, S. F., Yaylaoglu, M., Hussain, S., Cosino, E., Quiñones, G., Modrusan, Z. D., Seshagiri, S., Torres, E., et al. (2014) · Genes & Development · doi:10.1101/gad.237206.113 · Cited by 92
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 92
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 100
Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival
Fei, D. L., Motowski, H., Chatrikhi, R., Prasad, S., Yu, J., Gao, S., Kielkopf, C. L., Bradley, R. K., & VARMUS, H. E. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006384 · Cited by 90
Myeloid neoplasms with germline DDX41 mutation
Cheah, J., Hahn, C. N., Hiwase, D., Scott, H. S., & Brown, A. L. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2260-y · Cited by 90
Myelodysplastic syndromes
Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96
Molecular Pathophysiology of Myelodysplastic Syndromes
Lindsley, R. C., & Ebert, B. L. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132436 · Cited by 88
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells
Raffel, S., Klimmeck, D., Falcone, M., Demir, A., Pouya, A., Zeisberger, P., Lutz, C., Tinelli, M., Bischel, O. E., Bullinger, L., et al. (2020) · Blood · doi:10.1182/blood.2019003654 · Cited by 91
Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Togami, K., Chung, S. S., Madan, V., Booth, C. A. G., Kenyon, C. M., Cabal‐Hierro, L., Taylor, J., Kim, S. S., Griffin, G. K., Ghandi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1513 · Cited by 90
Self-citation
Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptomePreprint
Cherry, S. R., & Lynch, K. W. (2020) · Genes & Development · doi:10.1101/gad.338962.120 · Cited by 90
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
Cluzeau, T., Robert, G., Mounier, N., Karsenti, J. M., Dufies, M., Puissant, A., Jacquel, A., Renneville, A., Preudhomme, C., Cassuto, J. P., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.481 · Cited by 93
The impact of SF3B1 mutations in CLL on the DNA-damage response
Raa, G. D. T., Derks, I. A. M., Navrkalová, V., Skowrońska, A., Moerland, P. D., van Laar, J., Oldreive, C., Monsuur, H. N., Trbušek, M., Malčíková, J., et al. (2014) · Leukemia · doi:10.1038/leu.2014.318 · Cited by 86
A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome
Bondu, S., Alary, A.-S., Lefèvre, C., Houy, A., Jung, G., Lefebvre, T., Rombaut, D., Boussaid, I., Bousta, A., Guillonneau, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5467 · Cited by 85
The evolving genomic landscape of myeloproliferative neoplasms
Nangalia, J., & Green, T. R. (2014) · Hematology · doi:10.1182/asheducation-2014.1.287 · Cited by 87
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Taylor, J., & Lee, S. C.-W. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22784 · Cited by 88
Recurrent SRSF2 mutations in MDS affect both splicing and NMDPreprint
Rahman, M. A., Lin, K., Bradley, R. K., Abdel-Wahab, O. I., & Krainer, A. R. (2020) · Genes & Development · doi:10.1101/gad.332270.119 · Cited by 85
A dynamic alternative splicing program regulates gene expression during terminal erythropoiesis
Pimentel, H., Parra, M., Gee, S. L., Ghanem, D., An, X., Li, J., Mohandas, N., Pachter, L. S., & Conboy, J. G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1388 · Cited by 88
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
Ochi, Y., Yoshida, K., Huang, Y., Kuo, M., Nannya, Y., Sasaki, K., Mitani, K., Hosoya, N., Hiramoto, N., Ishikawa, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23097-w · Cited by 85
Self-citation
Limiting of the Innate Immune Response by SF3A-Dependent Control of MyD88 Alternative mRNA Splicing
Arras, L. D., & Alper, S. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003855 · Cited by 88
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
Sun, Q.-Y., Ding, L.-W., Tan, K. T., Chien, W., Mayakonda, A., Lin, D.-C., Loh, X.-Y., Xiao, J.-F., Meggendorfer, M., Alpermann, T., et al. (2016) · Leukemia · doi:10.1038/leu.2016.160 · Cited by 87
Self-citation
The role of RNA alternative splicing in regulating cancer metabolism
Kozlovski, I., Siegfried, Z., Amar-Schwartz, A., & Karni, R. (2017) · Human Genetics · doi:10.1007/s00439-017-1803-x · Cited by 83
Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice
Kon, A., Yamazaki, S., Nannya, Y., Kataoka, K., Ota, Y., Nakagawa, M. M., Yoshida, K., Shiozawa, Y., Morita, M., Yoshizato, T., et al. (2017) · Blood · doi:10.1182/blood-2017-01-762393 · Cited by 90
Self-citation
Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes
Ochi, Y., Kon, A., Sakata, T., Nakagawa, M. M., Nakazawa, N., Kakuta, M., Kataoka, K., Koseki, H., Nakayama, M., Morishita, D., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0982 · Cited by 86
Self-citation
Perspective in Alternative Splicing Coupled to Nonsense-Mediated mRNA Decay
García-Moreno, J. F., & Romão, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249424 · Cited by 88
SRSF2 plays an unexpected role as reader of m5C on mRNA, linking epitranscriptomics to cancer
Ma, H., Bizet, M., Costa, C. S. D., Murisier, F., de Bony, E. J., Wang, M., Yoshimi, A., Lin, K., Riching, K. M., Wang, X., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.003 · Cited by 85
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
Lin, C., Hou, H., Chou, W., Kuo, Y., Liu, C., Chen, C., Lai, Y.-J., Tseng, M., Huang, C., Chiang, Y., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23596 · Cited by 85
Regulation of the CRL4Cdt2 Ubiquitin Ligase and Cell-Cycle Exit by the SCFFbxo11 Ubiquitin Ligase
Rossi, M., Duan, S., Jeong, Y., Horn, M., Saraf, A., Florens, L. A., Washburn, M. P., Antebi, A., & Pagano, M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.004 · Cited by 83
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia
Kar, S. A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M. G., Guinta, K. M., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.064048 · Cited by 88
Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer
Inoue, K., & Fry, E. A. (2015) · Genetics & Epigenetics · doi:10.4137/geg.s35500 · Cited by 84
Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3′ splice sites within RNA secondary structures
Kesarwani, A. K., Ramirez, O., Gupta, A. K., Yang, X., Murthy, T., Minella, A. C., & Pillai, M. M. (2016) · Oncogene · doi:10.1038/onc.2016.279 · Cited by 86
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population
van Zeventer, I. A., de Graaf, A. O., Salzbrunn, J. B., Nolte, I. M., Kamphuis, P., Dinmohamed, A. G., van der Reijden, B. A., Schuringa, J. J., Jansen, J. H., & Huls, G. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.006 · Cited by 85
Biallelic DICER1 Mutations in Sporadic Pleuropulmonary Blastoma
Seki, M., Yoshida, K., Shiraishi, Y., Shimamura, T., Sato, Y., Nishimura, R., Okuno, Y., Chiba, K., Tanaka, H., Kato, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2470 · Cited by 82
Self-citation
Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia
Hou, H., Liu, C., Kuo, Y., Chou, W., Tsai, C., Lin, C., Lin, L., Tseng, M., Chiang, Y., Liu, M.-C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7000 · Cited by 84
Age-related epigenetic drift in the pathogenesis of MDS and AMLPreprint
Maegawa, S., Gough, S. M., Watanabe‐Okochi, N., Lu, Y., Zhang, N., Castoro, R. J., Estecio, M. R., Jelı́nek, J., Liang, S., Kitamura, T., et al. (2014) · Genome Research · doi:10.1101/gr.157529.113 · Cited by 83
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications
Damm, F., Thol, F. R., Kosmider, O., Kade, S., Löffeld, P., Dreyfus, F., Stamatoullas, A., Schmidt, A., Beyne‐Rauzy, O., de Botton, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.321 · Cited by 83
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis ( RARS ‐ T ): 2017 update on diagnosis, risk‐stratification, and management
Patnaik, M. M., & Tefferi, A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24637 · Cited by 81
Myelodysplastic Syndrome Updated
Hasserjian, R. P. (2018) · Pathobiology · doi:10.1159/000489702 · Cited by 81
Gene expression and risk of leukemic transformation in myelodysplasia
Shiozawa, Y., Malcovati, L., Gallì, A., Pellagatti, A., Karimi, M., Sato‐Otsubo, A., Sato, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2017) · Blood · doi:10.1182/blood-2017-05-783050 · Cited by 82
Self-citation
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
Geyer, J. T., Tam, W., Liu, Y.-C., Chen, Z., Wang, S. A., Bueso-Ramos, C., Oak, J. S., Arber, D. A., Hsi, E. D., Rogers, H. J., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.45 · Cited by 80

Authors: Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.-K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H. P., Shih, L.-Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S., & Ogawa, S.
Affiliations: The University of Tokyo (JP)
Institute of Medical Science, The University of Tokyo (JP)
Heidelberg University (DE)
Japan Science and Technology Agency (JP)
University of Tsukuba (JP)
Tokyo Metropolitan Ohtsuka Hospital (JP)
SHOWA Medical University Fujigaoka Hospital (JP)
Munich Leukemia Laboratory (Germany) (DE)
Cedars-Sinai Medical Center (US)
Chang Gung University (TW)
Corresponding author: Ogawa, Seishi
ORCID: Yoshida, Kenichi
Sanada, Masashi
Shiraishi, Yuichi
Nowak, Daniel
Nagata, Yasunobu
Sato, Yusuke
Kon, Ayana
Nagasaki, Masao
Suzuki, Yutaka
Yamaguchi, Tomoyuki
Otsu, Makoto
Obara, Naoshi
Ishiyama, Ken
Nolte, Florian
Miyawaki, Shuichi
Sugano, Sumio
Haferlach, Claudia
Koeffler, H. Phillip
Shih, Lee-Yung
Haferlach, Torsten
Chiba, Shigeru
Nakauchi, Hiromitsu
Miyano, Satoru
Ogawa, Seishi
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2011-09-11
Volume: 478
Issue: 7367
Pages: 64-69
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature10496
OpenAlex: W2073889874
Cited by: 2,029
References: 37
Citations by year: 2026: 71 · 2025: 76 · 2024: 121 · 2023: 101 · 2022: 139 · 2021: 160 · 2020: 148 · 2019: 135 · 2018: 135 · 2017: 148 · 2016: 146 · 2015: 145 · 2014: 173 · 2013: 171 · 2012: 135
FWCI: 64.98
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
National University of Singapore (submittedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Japan Society for the Promotion of Science (22390191, 23791075, 22790895, 23659533, 23659482, 23390269, 23791068, 22659058)
National Cancer Institute (R01CA026038)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: myelodysplastic syndrome, splicing mutation, U2AF35, ZRSR2, SRSF2, SF3B1, 3' splice site recognition, pre-mRNA splicing, hematopoiesis, acute myeloid leukemia, myeloid neoplasms, aberrant splicing, therapeutic target
MeSH terms: Splicing Factor U2AF, Hematopoiesis, Humans, Mutation, Myelodysplastic Syndromes, Nuclear Proteins, Ribonucleoproteins, RNA Splicing, Spliceosomes, Alternative Splicing, Polymorphism, Single Nucleotide, RNA Splice Sites, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Frequent pathway mutations of splicing machinery in myelodysplasia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks